REDWOOD CITY, Calif.,
Dec. 21, 2017 /PRNewswire/ -- Genomic
Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, chairman of the board, chief
executive officer and president, will present at the
36th Annual J.P. Morgan Healthcare Conference at the
Westin St. Francis Hotel in San
Francisco on Monday, January 8,
2018 at 9:00 a.m. Pacific
Time.
To access the live and subsequently archived webcast of the
presentation, go to the Investor Relations section of the company's
web site at http://investor.genomichealth.com. Please connect to
the web site at least 15 minutes prior to the presentation to allow
for any software download that may be necessary. An archived replay
will be available for three months beginning 24 hours after the
live presentation.
About Genomic Health
Genomic Health, Inc.
(NASDAQ: GHDX) is the world's leading provider of genomic-based
diagnostic tests that help optimize cancer care, including
addressing the overtreatment of the disease, one of the greatest
issues in healthcare today. With its Oncotype
IQ® Genomic Intelligence Platform, the company is
applying its world-class scientific and commercial expertise and
infrastructure to lead the translation of clinical and genomic big
data into actionable results for treatment planning throughout the
cancer patient journey, from diagnosis to treatment selection and
monitoring. The Oncotype IQ portfolio of genomic tests and services
currently consists of the company's flagship line of Oncotype
DX ® gene expression tests that have been used
to guide treatment decisions for more than 800,000 cancer patients
worldwide. Genomic Health is expanding its test portfolio
to include additional liquid- and tissue-based tests, including the
recently launched Oncotype SEQ® Liquid
Select™ test. The company is based in Redwood City, California, with
international headquarters in Geneva, Switzerland. For
more information, please visit, www.GenomicHealth.com and
follow the company on
Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially,
and reported results should not be considered as an indication of
future performance. These risks and uncertainties are set forth in
our filings with the Securities and Exchange Commission, including
our most recent report on Form 10-Q for the quarter ended
September 30, 2017. These
forward-looking statements speak only as of the date hereof.
Genomic Health disclaims any obligation to update these
forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX,
Recurrence Score, DCIS Score, Oncotype SEQ, Liquid Select, Genomic
Prostate Score, Oncotype DX AR-V7 Nucleus Detect and Oncotype IQ
are trademarks or registered trademarks of Genomic Health, Inc. All
other trademarks and service marks are the property of their
respective owners.
GHDX-F
View original content with
multimedia:http://www.prnewswire.com/news-releases/genomic-health-to-present-at-the-36th-annual-jp-morgan-healthcare-conference-300572884.html
SOURCE Genomic Health, Inc.